Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nurix’s $120m Venture Round Will Bring Two Protein-Modulating Therapies To Clinic

Executive Summary

Company’s technology harnesses E3 ligases to either degrade dysregulated proteins or inhibit a specific ligase to increase substrate protein levels for therapeutic benefit.

You may also be interested in...



Monte Rosa Hits The Heights With $96m Cash Hike

The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.

Protein Degradation Leader Nurix Prepares First Clinical Trial

After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.

Finance Watch: With Four More IPOs, July May Match Or Exceed June’s 14

Public Company Edition: iTeos, Annexon, Nurix and Inozyme went public on 23 July and now CureVac has added its name to the IPO queue for what could be a large offering. Also, BioNTech raises $511.5m as COVID-19 vaccine progresses and PTC gets $650m from sale of risdiplam royalties. 

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel